Drug Trial Radar · NCT02262169
DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers
Last checked: Nov 19, 2026Latest source record: Jul 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
32
Actual
Start
Oct 2014
Primary completion
Feb 2019
Study completion Mar 2019
Sponsor
- Lead sponsor
- Dexa Medica GroupIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-arm, prospective, double-blind, double-dummy, randomized-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), or omeprazole at a dose of 40 mg once daily (before morning meal), for an 8-week course of therapy, for the treatment of patients with any non-bleeding peptic ulcers. DLBS2411 is a bioactive fraction of an Indonesian native herbal, Cinnamomum burmanii, locally known as kayu manis have been proven at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its gastro-protective defense mechanism works through the promotion of COX-2 derived prostaglandin (PgE2) synthesis, stimulating gastric-epithelial mucous and bicarbonate secretion; anti-oxidative activity; and endothelial-nitric oxide (NO) formation. Recent study of DLBS2411 in healthy volunteers demonstrated the effective role and safety of DLBS2411 in suppressing intragastric acidity. Having such mechanisms of action, DLBS2411 is hypothesized to benefit in peptic ulcers.
Conditions
- Non-Bleeding Peptic Ulcers
Interventions
OmeprazoleDrug
2 Omeprazole capsules 20 mg, once daily
Placebo caplet of DLBS2411Drug
1 placebo caplet of DLBS2411, twice daily
DLBS2411Drug
1 DLBS2411 caplet 250 mg, twice daily
Placebo capsule of OmeprazoleDrug
2 placebo capsules of Omeprazole, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Endoscopic ulcer healing rateTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Udayana Sanglah General Hospital
Denpasar, Bali, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.